This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN) – The pharmaceutical giant’s IMFINZI drug has received US FDA approval for stage 3 non-small cell lung cancer (after chemo/radiation), having showed showing 11.2 month improvement in progression free survival versus a placebo. It is the first immunotherapy drug to receive this level of approval.
Petra Diamonds (PDL) – The diamond miner has warned that full-year earnings will be 10-15% lower than market expectations, coming just three weeks after another profits warning.
Reckitt Benckiser (RB.) – The household goods behemoth has announced flat like-for-like sales in the fourth quarter, however also saw 2 per cent revenue growth on an underlying basis for the final quarter. The company was bolstered by its takeover of US company Mead Johnson and is currently undergoing a reform of its core businesses.
Saga (SAGA) – The over-50s insurance and holiday provider has appointed Patrick O’Sullivan, ex-Old Mutual chief, as its new Chairman.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| BALFOUR BEATTY | BBY | 3.3% | 3.4% | 1.3% |
| RIO TINTO | RIO | 1.9% | 3.1% | 1.5% |
| SEGRO | SGRO | 6.8% | 7.4% | 3.0% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research